Skip to main content

Table 1 Patient demographics and tumor characteristics by treatment arm

From: A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

  Standard
(N = 16)
Experimental
(N = 14)
Total
(N = 30)
p value
Median age, years (range) 57.2 (39.6–74.9) 53.1 (27.8–69.7) 54.7 (27.8–74.9) 0.42
Race/ethnicity     0.71
 Caucasian 11 (68.8%) 7 (50.0%) 18 (60.0%)  
 Hispanic 4 (25.0%) 5 (35.7%) 9 (30.0%)  
 African American 0 (0.0%) 1 (7.1%) 1 (3.3%)  
 Asian 1 (6.3%) 1 (7.1%) 2 (6.7%)  
Tumor type     0.21
 Invasive ductal carcinoma 16 (100%) 12 (85.7%) 28 (93.3%)  
 Invasive lobular carcinoma 0 (0.0%) 1 (7.1%) 1 (3.3%)  
 Invasive mammary carcinoma 0 (0.0%) 1 (7.1%) 1 (3.3%)  
Stage     0.72
 Stage II 7 (43.8%) 8 (57.1%) 15 (50.0%)  
 Stage III 9 (56.3%) 6 (42.9%) 15 (50.0%)  
Hormone status     
 ER negative 8 (50%) 6 (43%) 14 (46.6%)  
 ER positive 8 (50%) 8 (57.1%) 16 (53.3%)  
Grade     0.27
 Grade 2 5 (31.3%) 8 (57.1%) 13 (43.3%)  
 Grade 3 11 (68.8%) 6 (42.9%) 17 (56.7%)  
 Ki-67 50.5 (2--80) 55.9 (15–80) 53.2 (15–80) 0.54